» Articles » PMID: 33664298

Knocking out Alpha-synuclein in Melanoma Cells Dysregulates Cellular Iron Metabolism and Suppresses Tumor Growth

Overview
Journal Sci Rep
Specialty Science
Date 2021 Mar 5
PMID 33664298
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The protein alpha-synuclein (α-syn) is unusual because, depending on its conformation and the type of cell in which it is expressed, it is pro-death or pro-survival, triggering neurodegeneration in Parkinson's disease and enhancing cell survival of some melanomas. To probe the function of α-syn in melanoma, we used CRISPR/Cas9 to knockout SNCA, the gene that codes for α-syn, in SK-Mel-28 melanoma cells. The SNCA-knockout clones in culture exhibited a decrease in the transferrin receptor 1 (TfR1), an increase in ferritin, an increase of reactive oxygen species and proliferated slower than control cells. These SNCA-knockout clones grafted into SCID mice grew significantly slower than the SK-Mel-28 control cells that expressed α-syn. In the excised SNCA-knockout xenografts, TfR1 decreased 3.3-fold, ferritin increased 6.2-fold, the divalent metal ion transporter 1 (DMT1) increased threefold, and the iron exporter ferroportin (FPN1) decreased twofold relative to control xenografts. The excised SNCA-KO tumors exhibited significantly more ferric iron and TUNEL staining relative to the control melanoma xenografts. Collectively, depletion of α-syn in SK-Mel-28 cells dysregulates cellular iron metabolism, especially in xenografts, yielding melanoma cells that are deficient in TfR1 and FPN1, that accumulate ferric iron and ferritin, and that undergo apoptosis relative to control cells expressing α-syn.

Citing Articles

Identification and validation of five ferroptosis-related molecular signatures in keloids based on multiple transcriptome data analysis.

Sun Z, Qin Y, Zhang X Front Mol Biosci. 2025; 11():1490745.

PMID: 39834787 PMC: 11743277. DOI: 10.3389/fmolb.2024.1490745.


Nuclear Alpha-Synuclein in Parkinson's Disease and the Malignant Transformation in Melanoma.

Jimenez-Capdeville M, Chi-Ahumada E, Garcia-Ortega F, Castanedo-Cazares J, Norman R, Rodriguez-Leyva I Neurol Res Int. 2025; 2025:1119424.

PMID: 39816956 PMC: 11729518. DOI: 10.1155/nri/1119424.


Bioinformatic analysis of ferroptosis related biomarkers and potential therapeutic targets in vitiligo.

Liu L, Deng L, Guan L, Hu Y, Li Q, Yu C Sci Rep. 2025; 15(1):2035.

PMID: 39814853 PMC: 11735852. DOI: 10.1038/s41598-025-86061-4.


Alpha-synuclein knockout impairs melanoma development and alters DNA damage repair in the TG3 mouse model in a sex-dependent manner.

Arnold M, Chen S, Unni V bioRxiv. 2024; .

PMID: 39677631 PMC: 11642733. DOI: 10.1101/2024.12.01.626256.


Transcriptomic analysis of melanoma cells reveals an association of α-synuclein with regulation of the inflammatory response.

Rajasekaran S, Cheng S, Gajendran N, Shekoohi S, Chesnokova L, Yu X Sci Rep. 2024; 14(1):27140.

PMID: 39511366 PMC: 11544018. DOI: 10.1038/s41598-024-78777-6.


References
1.
Chandra S, Chen X, Rizo J, Jahn R, Sudhof T . A broken alpha -helix in folded alpha -Synuclein. J Biol Chem. 2003; 278(17):15313-8. DOI: 10.1074/jbc.M213128200. View

2.
Turriani E, Lazaro D, Ryazanov S, Leonov A, Giese A, Schon M . Treatment with diphenyl-pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death. Proc Natl Acad Sci U S A. 2017; 114(25):E4971-E4977. PMC: 5488931. DOI: 10.1073/pnas.1700200114. View

3.
Sekigawa A, Fujita M, Sekiyama K, Takamatsu Y, Hatano T, Rockenstein E . Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H β-synuclein. Mol Brain. 2012; 5:34. PMC: 3546907. DOI: 10.1186/1756-6606-5-34. View

4.
Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton M, Sudhof T . Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010; 329(5999):1663-7. PMC: 3235365. DOI: 10.1126/science.1195227. View

5.
Pan T, Li X, Jankovic J . The association between Parkinson's disease and melanoma. Int J Cancer. 2011; 128(10):2251-60. DOI: 10.1002/ijc.25912. View